Submit the sBLA for Dupixent in bullous pemphigoid
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 31 Oct 2024
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“BP sBLA submission planned for fourth quarter 2024”
What we found
Evidence strength A What the grades mean
Two later 8-K filings state the Dupixent bullous pemphigoid sBLA was submitted in Q4 2024, meeting the deadline; no exact date is given.
-
A Regeneron Pharmaceuticals 8-K filed 2025-01-13
“for which a supplemental Biologics License Application (sBLA) was submitted in the fourth quarter of 2024” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 8-K filed 2025-02-04
“An sBLA for Dupixent in bullous pemphigoid was submitted to the FDA.” ✓ confirmed on the page
Market reaction: the shares moved -1.2% against the S&P 500 over the three sessions around the disclosure (10 Jan 2025 to 15 Jan 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- Dupixent bullous pemphigoid sBLA submission
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-REGN-006349 · Corrections policy